glp 1 receptor agonists in idiopathic intracranial hypertension and the Challenge of Weight Loss Effect of glucagon like peptide-1

Elmets CA et al (2021) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

GLP-1 receptor agonists also suppress glucagon secretion from pancreatic alpha cells, slow gastric emptying, and promote satiety through central nervous system pathways

Most people naturally produce enough GLP-1 to keep your blood sugar in check

These drugs have also caused new or worsening kidney disease, including kidney failure, in some people

The dosage may be increased to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level based on treatment response and tolerability, according to the FDA

There appear to be multiple pathways that GLP-1 agonists directly and indirectly target that cause a multitude of downstream effects in terms of immune, inflammatory and cellular health as Ive just highlighted